Chargement en cours...
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Advances in the understanding of the molecular basis for acute myeloid leukemia (AML) have generated new potential targets for treatment. Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are associated with poor overall survival. AXL pla...
Enregistré dans:
| Publié dans: | Invest New Drugs |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer US
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5613053/ https://ncbi.nlm.nih.gov/pubmed/28516360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0470-z |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|